echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > J Invest Dermatol: Inhibition of glucose metabolism can relieve acquired bullous pemphigoid epidermolysis

    J Invest Dermatol: Inhibition of glucose metabolism can relieve acquired bullous pemphigoid epidermolysis

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Research evidence shows that the differentiation and function of immune cells are affected by cell metabolism, and vice versa , which is a prerequisite for immune response.


    Immune differentiation and function of cells of the affected cell metabolism, and vice versa immune differentiation, and function of cells of the affected cell metabolism, and vice versaimmunization

    Acquired bullous pemphigoid epidermolysis (EBA) is an autoantibody-driven, granulocyte-mediated skin disease.


    Acquired bullous pemphigoid epidermolysis (EBA) is an autoantibody-driven, granulocyte-mediated skin disease.


    Paul et al.


    Metformin

    Metformin and 2-deoxyglucose can reduce BP-like EBA

    Metformin and 2-deoxyglucose can reduce BP-like EBA

    Both metformin and 2-deoxyglucose can reduce the severity of the BP-like EBA antibody transfer model.


    Both metformin and 2-deoxyglucose can reduce the severity of the BP-like EBA antibody transfer model.


    The neutrophil response triggered by IC requires the participation of aerobic glycolysis and OxPhos

    The neutrophil response triggered by IC requires the participation of aerobic glycolysis and OxPhos

    By reducing OxPhos, metformin can also inhibit this neutrophil response, but only when overdose does it have this effect, which makes it unlikely that metformin will have a direct effect on neutrophils in the body.


    All in all, the results of the study emphasized that neutrophil glycolysis and OxPhos are potential targets for the treatment of EBA, and 2-deoxyglucose and metformin are potential drugs.


    The results of this study emphasize that glycolysis of neutrophils and OxPhos are potential targets for the treatment of EBA, and 2-deoxyglucose and metformin are potential drugs.


    Original source:

    Schilf Paul, Schmitz Marie, Derenda-Hell Aleksandra et al.


    org/10.
    1016/j.
    jid.
    2021.
    01.
    014">Inhibition of glucose metabolism abrogates the effector phase of bullous pemphigoid-like epidermolysis bullosa acquisita in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.